Not sure I can provide any particular insight on this.
However, I would point out that in the potential pipeline shown in the presentation, glaucoma and LHON are listed as two examples of blinding eye diseases that might be treatable with PYC-001.
This suggests to me that these two indications haven’t been firmly decided; nor does it necessarily rule out acute ischemic optic neuropathy or other “blinding eye diseases where its mechanism of improving cellular bioenergetics holds potential for disease correction”.
Were the PYC-001 asset to be licensed out, I guess it would be the licensee’s call as to which indications would be pursued.
PYC Price at posting:
13.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)